Corline Biomedical AB (ST:CLBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Corline Biomedical AB (CLBIO)
Corline Biomedical AB (ST:CLBIO) has a market capitalization of $48.79 Million (Skr453.36 Million) as of August 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #21933 globally and #411 in its home market, demonstrating a 0.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Corline Biomedical AB's stock price Skr17.70 by its total outstanding shares 25613551 (25.61 Million). See CLBIO capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Corline Biomedical AB Market Cap History: 2015 to 2026
Corline Biomedical AB's market capitalization history from 2015 to 2026. Data shows growth from $32.18 Million to $48.79 Million (4.69% CAGR).
Index Memberships
Corline Biomedical AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.92 Billion | 0.31% | #64 of 281 |
Weight: Corline Biomedical AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Corline Biomedical AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Corline Biomedical AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.91x
Corline Biomedical AB's market cap is 5.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $27.84 Million | $947.00K | -$5.25 Million | 29.40x | N/A |
| 2017 | $33.77 Million | $638.00K | -$7.81 Million | 52.93x | N/A |
| 2018 | $50.44 Million | $1.56 Million | -$6.79 Million | 32.27x | N/A |
| 2019 | $41.35 Million | $1.06 Million | -$9.54 Million | 38.86x | N/A |
| 2020 | $41.21 Million | $3.70 Million | -$7.29 Million | 11.15x | N/A |
| 2021 | $40.24 Million | $7.06 Million | -$6.92 Million | 5.70x | N/A |
| 2022 | $25.41 Million | $23.55 Million | $2.33 Million | 1.08x | 10.91x |
| 2023 | $41.07 Million | $25.03 Million | -$1.81 Million | 1.64x | N/A |
| 2024 | $24.20 Million | $9.78 Million | -$23.19 Million | 2.48x | N/A |
| 2025 | $45.21 Million | $7.65 Million | -$14.71 Million | 5.91x | N/A |
Competitor Companies of CLBIO by Market Capitalization
Companies near Corline Biomedical AB in the global market cap rankings as of August 5, 2026.
Key companies related to Corline Biomedical AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Corline Biomedical AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Corline Biomedical AB's market cap moved from $32.18 Million to $ 48.79 Million, with a yearly change of 4.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr48.79 Million | +7.93% |
| 2025 | Skr45.21 Million | +86.79% |
| 2024 | Skr24.20 Million | -41.07% |
| 2023 | Skr41.07 Million | +61.61% |
| 2022 | Skr25.41 Million | -36.85% |
| 2021 | Skr40.24 Million | -2.34% |
| 2020 | Skr41.21 Million | -0.33% |
| 2019 | Skr41.35 Million | -18.03% |
| 2018 | Skr50.44 Million | +49.39% |
| 2017 | Skr33.77 Million | +21.29% |
| 2016 | Skr27.84 Million | -13.50% |
| 2015 | Skr32.18 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Corline Biomedical AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.79 Million USD |
| MoneyControl | $48.79 Million USD |
| MarketWatch | $48.79 Million USD |
| marketcap.company | $48.79 Million USD |
| Reuters | $48.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products … Read more